Identification of prognostic factors in patients with metastatic gastrointestinal stromal tumors
dc.contributor.buuauthor | Çubukçu, Erdem | |
dc.contributor.buuauthor | Ölmez, Ömer Fatih | |
dc.contributor.buuauthor | Avcı, Nilüfer | |
dc.contributor.buuauthor | Canhoroz, Mustafa | |
dc.contributor.buuauthor | Kurt, Ender | |
dc.contributor.buuauthor | Kanat, Özkan | |
dc.contributor.buuauthor | Evrensel, Türkkan | |
dc.contributor.buuauthor | Manavoǧlu, Osman | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı. | tr_TR |
dc.contributor.orcid | 0000-0002-9732-5340 | tr_TR |
dc.contributor.researcherid | AAJ-1027-2021 | tr_TR |
dc.contributor.scopusid | 53986153800 | tr_TR |
dc.contributor.scopusid | 26435400000 | tr_TR |
dc.contributor.scopusid | 55390409800 | tr_TR |
dc.contributor.scopusid | 52663246200 | tr_TR |
dc.contributor.scopusid | 7006207332 | tr_TR |
dc.contributor.scopusid | 55881548500 | tr_TR |
dc.contributor.scopusid | 6603942124 | tr_TR |
dc.contributor.scopusid | 6602587152 | tr_TR |
dc.date.accessioned | 2022-01-19T12:22:50Z | |
dc.date.available | 2022-01-19T12:22:50Z | |
dc.date.issued | 2012 | |
dc.description.abstract | Purpose: Gastrointestinal stromal tumors (GISTs) have a complex biology which is reflected by a marked clinical heterogeneity. Thus, there has been great interest in identifying prognostic factors influencing tumor recurrence and survival. The aim of this study was to identify potential clinical and immunohistochemical prognostic factors that may affect survival and treatment outcomes inpatients with metastatic GISTs. Methods: Between 2000 and September 2011, a total of 41 patients with metastatic GISTs (29 males and 12 females; mean age: 57.4 +/- 11.8 years; range 29-74) were referred to the Department of Oncology, Uludag University Medical School. Survival analysis for a number of potential prognostic factors was made with the main outcome results of progression-free survival (PFS) and overall survival (OS). Results: The most common sites of isolated metastases comprised the liver (n=18), followed by lymph nodes (n=5), the omentum (n=1), and the mesothelium (n=1). The remaining patients had metastases at multiple sites. Cox regression analysis identified ileal location as the only significant predictor of poor PFS both after first-line (p=0.023) and second-line therapy (p=0.016). Tumor location in the ileum (p=0.025) and S100 immunoreactivity (p=0.041) were both independent predictors of OS. Conclusion: Tumor site and S100 positivity were the main significant independent predictors of clinical outcomes in patients with metastatic GISTs treated by standard of care. | en_US |
dc.identifier.citation | Çubukçu, E. vd. (2012). "Identification of prognostic factors in patients with metastatic gastrointestinal stromal tumors". Journal of BUON, 17(3), 517-521. | en_US |
dc.identifier.endpage | 521 | tr_TR |
dc.identifier.issn | 1107-0625 | |
dc.identifier.issn | 2241-6293 | |
dc.identifier.issue | 3 | tr_TR |
dc.identifier.pubmed | 23033292 | tr_TR |
dc.identifier.scopus | 2-s2.0-84867492647 | tr_TR |
dc.identifier.startpage | 517 | tr_TR |
dc.identifier.uri | http://hdl.handle.net/11452/24169 | |
dc.identifier.volume | 17 | tr_TR |
dc.identifier.wos | 000309793000018 | |
dc.indexed.pubmed | Pubmed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Imprimatur Publications | en_US |
dc.relation.journal | Journal of BUON | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Oncology | en_US |
dc.subject | Gastrointestinal stromal tumors | en_US |
dc.subject | Prognosis | en_US |
dc.subject | S100 marker | en_US |
dc.subject | Tumor location | en_US |
dc.subject | Differential-diagnosis | en_US |
dc.subject | Molecular pathology | en_US |
dc.subject | Different sites | en_US |
dc.subject | S100 proteins | en_US |
dc.subject | Gist | en_US |
dc.subject | Morphology | en_US |
dc.subject | Consensus | en_US |
dc.subject | Survival | en_US |
dc.subject | Cancer | en_US |
dc.subject.emtree | Imatinib | en_US |
dc.subject.emtree | Protein s 100 | en_US |
dc.subject.emtree | Sunitinib | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Aged | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Cancer patient | en_US |
dc.subject.emtree | Cancer prognosis | en_US |
dc.subject.emtree | Cancer survival | en_US |
dc.subject.emtree | Clinical article | en_US |
dc.subject.emtree | Clinical assessment | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Gastrointestinal stromal tumor | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Immunohistochemistry | en_US |
dc.subject.emtree | Immunoreactivity | en_US |
dc.subject.emtree | Leg edema | en_US |
dc.subject.emtree | Liver metastasis | en_US |
dc.subject.emtree | Lymph node metastasis | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Mesothelium | en_US |
dc.subject.emtree | Omentum | en_US |
dc.subject.emtree | Overall survival | en_US |
dc.subject.emtree | Progression free survival | en_US |
dc.subject.emtree | Proportional hazards model | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Aged | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Gastrointestinal neoplasms | en_US |
dc.subject.mesh | Gastrointestinal stromal tumors | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Middle aged | en_US |
dc.subject.mesh | Neoplasm metastasis | en_US |
dc.subject.mesh | Prognosis | en_US |
dc.subject.mesh | Proportional hazards models | en_US |
dc.subject.mesh | S100 proteins | en_US |
dc.subject.scopus | Gastrointestinal Stromal Tumors; Imatinib; Sunitinib | en_US |
dc.subject.wos | Oncology | en_US |
dc.title | Identification of prognostic factors in patients with metastatic gastrointestinal stromal tumors | en_US |
dc.type | Article | |
dc.wos.quartile | Q4 | en_US |